REGENXBIO Statistics
Total Valuation
REGENXBIO has a market cap or net worth of $463.74 million. The enterprise value is $344.36 million.
Important Dates
The last earnings date was Wednesday, November 6, 2024, after market close.
Earnings Date | Nov 6, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
REGENXBIO has 49.55 million shares outstanding. The number of shares has increased by 9.71% in one year.
Current Share Class | 49.55M |
Shares Outstanding | 49.55M |
Shares Change (YoY) | +9.71% |
Shares Change (QoQ) | +0.39% |
Owned by Insiders (%) | 7.58% |
Owned by Institutions (%) | 80.73% |
Float | 40.60M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 5.46 |
Forward PS | 1.97 |
PB Ratio | 1.58 |
P/TBV Ratio | 1.58 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 4.08 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.05, with a Debt / Equity ratio of 0.48.
Current Ratio | 3.05 |
Quick Ratio | 2.93 |
Debt / Equity | 0.48 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -52.13 |
Financial Efficiency
Return on equity (ROE) is -71.87% and return on invested capital (ROIC) is -29.81%.
Return on Equity (ROE) | -71.87% |
Return on Assets (ROA) | -26.03% |
Return on Capital (ROIC) | -29.81% |
Revenue Per Employee | $245,137 |
Profits Per Employee | -$694,201 |
Employee Count | 344 |
Asset Turnover | 0.15 |
Inventory Turnover | n/a |
Taxes
Income Tax | -152,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.67% in the last 52 weeks. The beta is 1.23, so REGENXBIO's price volatility has been higher than the market average.
Beta (5Y) | 1.23 |
52-Week Price Change | -53.67% |
50-Day Moving Average | 10.31 |
200-Day Moving Average | 14.25 |
Relative Strength Index (RSI) | 43.70 |
Average Volume (20 Days) | 877,817 |
Short Selling Information
The latest short interest is 4.91 million, so 9.91% of the outstanding shares have been sold short.
Short Interest | 4.91M |
Short Previous Month | 4.99M |
Short % of Shares Out | 9.91% |
Short % of Float | 12.09% |
Short Ratio (days to cover) | 9.78 |
Income Statement
In the last 12 months, REGENXBIO had revenue of $84.33 million and -$238.81 million in losses. Loss per share was -$5.00.
Revenue | 84.33M |
Gross Profit | -164.98M |
Operating Income | -240.08M |
Pretax Income | -241.23M |
Net Income | -238.81M |
EBITDA | -223.55M |
EBIT | -240.08M |
Loss Per Share | -$5.00 |
Full Income Statement Balance Sheet
The company has $255.46 million in cash and $145.81 million in debt, giving a net cash position of $132.76 million or $2.68 per share.
Cash & Cash Equivalents | 255.46M |
Total Debt | 145.81M |
Net Cash | 132.76M |
Net Cash Per Share | $2.68 |
Equity (Book Value) | 301.42M |
Book Value Per Share | 6.09 |
Working Capital | 210.67M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$182.26 million and capital expenditures -$2.48 million, giving a free cash flow of -$184.74 million.
Operating Cash Flow | -182.26M |
Capital Expenditures | -2.48M |
Free Cash Flow | -184.74M |
FCF Per Share | -$3.73 |
Full Cash Flow Statement Margins
Gross margin is -195.65%, with operating and profit margins of -284.70% and -283.19%.
Gross Margin | -195.65% |
Operating Margin | -284.70% |
Pretax Margin | -283.37% |
Profit Margin | -283.19% |
EBITDA Margin | -265.10% |
EBIT Margin | -284.70% |
FCF Margin | -218.67% |
Dividends & Yields
REGENXBIO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -9.71% |
Shareholder Yield | -9.71% |
Earnings Yield | -50.05% |
FCF Yield | -38.72% |
Analyst Forecast
The average price target for REGENXBIO is $36.36, which is 288.46% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $36.36 |
Price Target Difference | 288.46% |
Analyst Consensus | Strong Buy |
Analyst Count | 12 |
Revenue Growth Forecast (5Y) | 45.69% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
REGENXBIO has an Altman Z-Score of -1.22 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -1.22 |
Piotroski F-Score | 4 |